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aDITORIAL COMMENT
he Choice of Valve Protheses*
tuart W. Jamieson, MB, FRCS, FACC,
ichael M. Madani, MD
an Diego, California
he ideal prosthetic valve would have excellent hemody-
amics (similar to a normal human valve in the same
osition), last a lifetime, be free of structural dysfunction or
reakdown, and require no particular medical therapy such
s anticoagulation. Needless to say, such a valve is yet to be
vailable. However, valvular replacement is still relatively
oung—the first successful aortic valve replacement (a caged
all) was performed by Harken et al. in 1960 (1), and in the
ame year Starr and Edwards (2) successfully replaced the
itral valve using a caged ball valve of their own design. By
967, approximately 2,000 Starr-Edwards valves had been
mplanted, and the caged ball valve prosthesis was the
tandard.
See page 384
The first tissue valves used were homografts or xeno-
rafts, with the first homograft replacement being described
y Heimbecker et al. in Toronto in 1962 (3), using an aortic
omograft in the mitral position. Shumway and Lower (4)
escribed experiments in dogs in which they replaced the
itral valve with a pulmonary autograft, and Ross (5) in
967 described the clinical application of aortic replacement
ith a pulmonary autograft. The “Ross procedure” remains
dvocated by some for aortic valve replacement in certain
ituations (especially for younger patients) but turns a
elatively straightforward operation (standard aortic valve
eplacement) into a double valve replacement of some
omplexity, because the pulmonary deficit now has to be
eplaced with a homograft, and the coronary arteries re-
mplanted in the autograft.
After 1960, other autogenous materials were used to
anufacture biological prosthetic valves; these included
ericardium, fascia lata, and dura mater. In 1964, Duran
nd Gunning (6,7) replaced an aortic valve in a patient using
xenograft porcine aortic valve. Carpentier and associates
evived interest in xenograft valves by fixating porcine valves
ith glutaraldehyde. In addition, Carpentier also mounted
he aortic pig valves on a stent to produce a bioprosthesis.
rom then on, Carpentier-Edwards (CE) porcine valves
nd Hancock and Angell-Shiley bioprostheses became more
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Department of Surgery, Division of Cardiothoracic Surgery, Universitycf California San Diego, San Diego, California.nd more popular and were implanted in large numbers of
atients (8,9).
Before 1980, pericardial valve prostheses had been aban-
oned because of a high rate of valve failure as the result of
tructural deterioration. In 1979, Carpentier and the pres-
ntly called Edwards Lifesciences began the development of
pericardial valve in an attempt to improve upon the earlier
ericardial valve designs. The aortic CE pericardial valve
as introduced to clinical use in 1981 and approved for U.S.
ommercial distribution in September 1991 by the Food
nd Drug Administration. The pericardial valve is a biome-
hanically engineered valve—a stented valve with a biolog-
cal component. In this way, it differs from a porcine (pig)
tented valve, which incorporates the natural pig’s valve.
By 1995, the 10-year performance of this valve could be
ssessed (10–13). With intermediate follow-up showing
atisfactory outcome and results, use of this valve became
ore popular, and in many centers across the country it
ecame the biological valve of choice in the aortic position.
Debate on the choice between a mechanical versus tissue
alve continues, and although some guidelines are in place
or choosing one valve type over another, no definitive
riteria yet exist. Just as advances have been made in tissue
alves, newer generations of mechanical valves display dis-
inct advantages over those used historically. Better hemo-
ynamics and the possibility of lowering anticoagulation
evels with the newer mechanical valves continue the com-
etition and the debate of relative advantages of the me-
hanical or biological choice in various age groups.
Given the wide variety of tissue or mechanical valves
vailable in the market today, the decision to place a
articular valve may not be easy, and often is not based on
olid scientific data. Many different types of biological
rostheses remain available, such as porcine valves, pericar-
ial valves, stentless valves, homografts, and autografts; with
he porcine and pericardial stented valves being the most
idely used.
In this issue of the Journal, Gao et al. (14) describe their
xperience with the durability of porcine and pericardial
alves in the aortic position. Although in more recent years
hey have been using the pericardial valve exclusively, their
verall experience includes 518 isolated aortic valve replace-
ents with CE porcine valves and 1,021 replacements with
E pericardial valves. The porcine valves were placed
etween 1974 and 1996, and the pericardial valves between
991 and 2002. Both groups have similar clinical profiles,
nd specifically the age groups and the age distribution are
lmost identical in both groups. Patients were followed at
nnual intervals, and the follow-up was 91% complete.
lthough all valve-related complications and deaths were
efined and analyzed, the primary outcome of interest was
ioprosthetic valve dysfunction.
When the results were analyzed for both groups, the
uthors were able to show that survival and valve compli-
ations were similar in both groups. However, there was a
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Editorial Comment July 21, 2004:389–90ignificant difference in valve-related structural deterioration
nd dysfunction, as measured by freedom from explantation.
verall, the CE pericardial valve had a significantly superior
ate of freedom from explantation compared with the
orcine valve, with only four pericardial valves being ex-
lanted during the study period as a result of structural valve
eterioration (SVD).
Pericardial valves, as with xenografts valves, fail primarily
ecause of leaflet calcification (15), and the rate of leaflet
alcification with porcine valves has been shown to be
elated to the age of the patient. Jamieson et al. (16) in a
0-year follow-up of the porcine prosthesis showed that
ith the CE porcine valve the freedom from explant at 15
ears was significantly greater for patients 70 years of age
nd older. In the study presented here, the authors demon-
trate that age has a significant impact on the durability of
he porcine valve in the aortic position, as have others;
owever, the same effect could not be shown in the
ericardial group. This may be due to small number of
atients with SVD in that group.
Relative freedom from structural deterioration that was
ndependent of age would be a very important advance, and
ay confirm earlier studies with the pericardial valve.
osgrove et al. (10) believed in 1995 that age was not a
ignificant factor with 10-year follow-up of this valve, when
atients 65 and older were compared with patients younger
han 65. Similarly, Banbury et al. (17) showed excellent
reedom from SVD and concluded that patients as young as
5 would have10% chance of requiring explant before the
ge of 80.
One limitation of the current study is the fact that the
uthors have compared the second generation of pericardial
alves with the older generation of porcine valves available
n 1980s, and as the authors point out, they have exclusively
sed the pericardial valve in the last decade or so. This study
ould be more powerful if the patients had been random-
zed to either porcine or pericardial valves, with subsequent
ong-term follow-up. More importantly, because there are
ewer generations of tissue valves, including porcine valves
oth stented and stentless, the most effective study would be
o compare their long-term durability to the other types of
he newer valves available, in particular the pericardial valves
s well as mechanical valves.
In the absence of randomized trials, this study from the
tarr group is an important contribution to the literature.
he authors believe that the pericardial valve has superior
unction and durability compared with the traditional por-
ine valve. Perhaps the most valuable conclusion from this
tudy, and others similar to it, is that the durability of aissue valve, in particular the durability of pericardial valves
n the aortic position, is better than 90% at 10 years.
owever, the 10-year test is relatively easy to pass. Relative
reedom from structural deterioration at 20 years will be the
mportant milestone.
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